NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 101
(Total Views: 99)
Posted On: 07/02/2024 5:22:28 PM
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new data from its phase 3 PD study. According to the report, study findings indicate that buntanetap, the company’s proprietary drug candidate, is safe and effective in improving motor and nonmotor activities and improving cognitive functions in patients with early Parkinson’s disease. Specifically, buntanetap stopped cognitive decline in all enrolled patients and improved cognition in patients with mild dementia, improved motor and nonmotor PD-related functions in patients with a diagnosis of more than three years, and improved motor and nonmotor PD-related functions in patients with postural instability and gait difficulty (“PIGD”). Buntanetap targets neurodegeneration by hindering the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43. It also works to reverse neurodegeneration in AD, PD and other neurodegenerative diseases, restoring brain function and improving a patient’s quality of life. The company has scheduled a webcast today to discuss the study findings in more detail. The webcast will begin at 4:30 p.m. ET. “We are very pleased to see improvements in many of our patients over such a short course of treatment,” said Annovis Bio president and CEO Maria Maccecchini, PhD, in the press release. “These compelling data reinforce our commitment to advancing buntanetap into a longer study, which will allow us not only to verify observed symptomatic improvements but also to explore buntanetap’s disease-modifying properties.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new data from its phase 3 PD study. According to the report, study findings indicate that buntanetap, the company’s proprietary drug candidate, is safe and effective in improving motor and nonmotor activities and improving cognitive functions in patients with early Parkinson’s disease. Specifically, buntanetap stopped cognitive decline in all enrolled patients and improved cognition in patients with mild dementia, improved motor and nonmotor PD-related functions in patients with a diagnosis of more than three years, and improved motor and nonmotor PD-related functions in patients with postural instability and gait difficulty (“PIGD”). Buntanetap targets neurodegeneration by hindering the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43. It also works to reverse neurodegeneration in AD, PD and other neurodegenerative diseases, restoring brain function and improving a patient’s quality of life. The company has scheduled a webcast today to discuss the study findings in more detail. The webcast will begin at 4:30 p.m. ET. “We are very pleased to see improvements in many of our patients over such a short course of treatment,” said Annovis Bio president and CEO Maria Maccecchini, PhD, in the press release. “These compelling data reinforce our commitment to advancing buntanetap into a longer study, which will allow us not only to verify observed symptomatic improvements but also to explore buntanetap’s disease-modifying properties.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Anv Sec Group Inc. (ANVS) Stock Research Links
Scroll down for more posts ▼